Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Cowan A, et al. Among authors: nadeem o. Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6. Lancet Haematol. 2023. PMID: 36858677 Free PMC article.
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Richardson PG, Raje NS, El-Jawahri A. O'Donnell EK, et al. Among authors: nadeem o. Cancer. 2022 May 15;128(10):1996-2004. doi: 10.1002/cncr.34134. Epub 2022 Feb 15. Cancer. 2022. PMID: 35167125 Free article.
Melflufen for the treatment of multiple myeloma.
Ocio EM, Nadeem O, Schjesvold F, Gay F, Touzeau C, Dimopoulos MA, Richardson PG, Mateos MV. Ocio EM, et al. Among authors: nadeem o. Expert Rev Clin Pharmacol. 2022 Apr;15(4):371-382. doi: 10.1080/17512433.2022.2075847. Epub 2022 Jun 19. Expert Rev Clin Pharmacol. 2022. PMID: 35723075
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma.
O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Hu BY, Richardson PG, Raje NS, El-Jawahri A. O'Donnell EK, et al. Among authors: nadeem o. Blood Adv. 2022 Sep 13;6(17):4967-4974. doi: 10.1182/bloodadvances.2022007127. Blood Adv. 2022. PMID: 35848842 Free PMC article.
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Sklavenitis-Pistofidis R, et al. Among authors: nadeem o. Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017. Cancer Cell. 2022. PMID: 36379208 Free PMC article.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.
Dutta AK, Alberge JB, Lightbody ED, Boehner CJ, Dunford A, Sklavenitis-Pistofidis R, Mouhieddine TH, Cowan AN, Su NK, Horowitz EM, Barr H, Hevenor L, Beckwith JB, Perry J, Cao A, Lin Z, Kuhr FK, Mastro RGD, Nadeem O, Greipp PT, Stewart C, Auclair D, Getz G, Ghobrial IM. Dutta AK, et al. Among authors: nadeem o. Cancer Discov. 2023 Feb 6;13(2):348-363. doi: 10.1158/2159-8290.CD-22-0482. Cancer Discov. 2023. PMID: 36477267
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Ghobrial IM, et al. Among authors: nadeem o. Blood Cancer Discov. 2024 May 1;5(3):146-152. doi: 10.1158/2643-3230.BCD-24-0022. Blood Cancer Discov. 2024. PMID: 38441243
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
O'Donnell E, Mo C, Yee AJ, Nadeem O, Laubach J, Rosenblatt J, Munshi N, Midha S, Cirstea D, Chrysafi P, Horick N, Richardson PG, Raje N. O'Donnell E, et al. Among authors: nadeem o. Lancet Haematol. 2024 Apr 24:S2352-3026(24)00070-X. doi: 10.1016/S2352-3026(24)00070-X. Online ahead of print. Lancet Haematol. 2024. PMID: 38677302
43 results